Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients
| Autor: | Michele Caraglia, Serena Apollinari, Ornella Romano, Marco Pagliuchi, Cirino Botta, Ignazio Martellucci, Raffaele Addeo, Luca Luzzi, Gabriella Misso, Pierpaolo Correale, Giuseppe Gotti, Elena Bestoso, Pierosandro Tagliaferri, Maria Saveria Rotundo, Assunta Basile, Monica Lamberti, Antonella Licchetta, Alberto Abbruzzese |
|---|---|
| Přispěvatelé: | Correale P., Botta C., Basile A., Pagliuchi M., Licchetta A., Martellucci I., Bestoso E., Apollinari S., Addeo R., Misso G., Romano O., Abbruzzese A., Lamberti M., Luzzi L., Gotti G., Rotundo M.S., Caraglia M., Tagliaferri P., Correale, P, Botta, C, Basile, A, Pagliuchi, M, Licchetta, A, Martellucci, I, Bestoso, E, Apollinari, S, Addeo, R, Misso, Gabriella, Romano, O, Abbruzzese, A, Lamberti, Monica, Luzzi, L, Gotti, G, Rotundo, M, Caraglia, Michele, Tagliaferri, P. |
| Rok vydání: | 2011 |
| Předmět: |
Oncology
Adult Male Cancer Research medicine.medical_specialty Lung Neoplasms Bevacizumab Dose-dense chemotherapy Adenocarcinoma NSCLC Antibodies Monoclonal Humanized Drug Administration Schedule Internal medicine Carcinoma Non-Small-Cell Lung Antineoplastic Combined Chemotherapy Protocols Dose/dense-metronomic-chemotherapy medicine Humans Lung cancer Aged Etoposide Neoplasm Staging Pharmacology Cisplatin business.industry Cancer Antibodies Monoclonal mPEBev regimen Middle Aged medicine.disease VEGF Regimen Toxicity Carcinoma Squamous Cell Molecular Medicine Every Three Weeks Carcinoma Large Cell Female business medicine.drug |
| Zdroj: | Cancer biologytherapy. 12(2) |
| ISSN: | 1555-8576 |
| Popis: | Bevacizumab, is a humanized monoclonal antibody to vasculo-endothelial- growth-factor, with anticancer activity in non-small-cell-lung cancer (NSCLC) patients. Our previous results from a dose/finding phase I trial in NSCLC patients, demonstrated the anti-angiogenic effects and toxicity of a newest bevacizumab-based combination with fractioned cisplatin and daily oral etoposide. We designed a phase II trial to evaluate in advanced NSCLC patients the antitumor activity and the safety of this novel regimen. In particular, 45 patients (36 males and 9 females), with a mean age of 54 years, an ECOG ≤2, stage III B/IV and NSCLC (28 adenocarcinomas, 11 squamous-cell carcinomas, 2 large-cell carcinomas, 4 undifferentiated carcinomas), were enrolled. They received cisplatin (30 mg/sqm, days 1-3), oral etoposide (50 mg, days 1-15) and bevacizumab (5 mg/kg, day 3) every 3 weeks (mPEBev regimen). Patients who achieved an objective response or stable disease received maintenance treatment with bevacizumab in combination with erlotinib until progression. Grade I-II hematological, mucosal toxicity and alopecia were the most common adverse events. The occurrence of infections (17%), thromboembolic events (4.4%) and severe mood depression (6.7%) was also recorded. A partial response was achieved in 31 (68.8%) patients, disease remained stable in 8 (17.8%) and disease progressed in 6 (13.3%) with a progression-free-survival of 9.53 months (95% CI, 7.7-11.46). Our bio-chemotherapy regimen resulted very active in advanced NSCLC, however, the toxicity associated with the treatment requires strict selection of the patients to enroll in future studies. © 2011 Landes Bioscience. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|